Pemphigus Foliaceus—Repeated Treatment With Rituximab 7 Years After Initial Response: A Case Report

Frontiers in Medicine

Magdalena Kraft¹ 

关键词: pemphigus foliaceus;    rituximab;    anti-CD20;    b-cell depletion;    autoimmune blistering diseases;   

DOI  :  10.3389/fmed.2018.00315

学科分类：医学（综合）

来源: Frontiers

【 摘 要 】

Pemphigus foliaceus is an autoimmune skin disease mediated by autoantibodies directed against desmoglein-1 located in the upper epidermal layer. Rituximab, a monoclonal anit-CD20 antibody depleting b-cells, offers an effective treatment possibility for therapy-resistant pemphigus foliaceus. Here, we present the case of 55-year-old man who did not respond sufficiently to conventional treatment with prednisolone, azathioprine, and cyclophosphamide, but underwent almost complete remission after rituximab treatment. The patient relapsed 7 years later, and a repeated course of rituximab infusions led to a partial remission.

【 授权许可】

CC BY